Clinical Trials Logo

Clinical Trial Summary

This prospective single arm double-blind study approved by the Ethics Committee of the institution, will be conducted on at the Oncology Institute of Vojvodina in Sremska Kamenica, Serbia. Patients with colo-rectal cancer liver metastases (CRLM) is presented to the multi-disciplinary team (MDT).Screening and enrolment is conducted after established of indication for resection. The surgeons assesses resection margin (RM) for every resected liver specimen (RLS) intra-operatively by inspection and palpation. These data will be compared with pathological RM examination as a "gold standard". Resection margin of 1 mm or more will be rated as negative RM (RM-) otherwise RM is positive (RM+). Taking the result of the pathohistological examination as "gold standard" it is determined that RM is true positive when the pathologist and surgeon agreed that the RM is positive. False negative RM is when the surgeon assesses RM as negative and pathologist as positive. The sensitivity of the surgical assessment of RM+ is defined as the rate of RM+ which was correctly identified. True negative RM is determined when the pathologist and surgeon agreed that it is negative RM. False positive RM defined when the surgeon assessed RM as positive, but pathologist found that it was RM-. The specificity of the surgical assessment of RM is defined as the rate of RM- which is correctly identified. Total accuracy represents the rate of correctly recognized positive and negative RM, relative to the total number of samples. Agreement between surgeon and pathologists finding will be analyzed as well as difference between them. Disease recurrence and disease-free survival (DFS) will be analyzed by RM.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04634526
Study type Observational [Patient Registry]
Source Oncology Institute of Vojvodina
Contact Mladjan Protic, MD,PhD
Phone +381641253308
Email mlprotic@gmail.com
Status Recruiting
Phase
Start date April 18, 2018
Completion date January 1, 2026

See also
  Status Clinical Trial Phase
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT03562234 - The CLiFF Study: Change in Liver Function and Fat in Pre-operative Chemotherapy for Colorectal Liver Metastases
Recruiting NCT03732235 - TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer
Recruiting NCT06126419 - Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration N/A
Active, not recruiting NCT05616039 - I-FIGS Feasibility Study N/A
Withdrawn NCT05175092 - Living Donor Liver Transplantation for CRC Liver Metastases N/A
Recruiting NCT04798898 - Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation N/A
Not yet recruiting NCT06053996 - Hepatopulmonary Radio-sterilization With Immunotherapy N/A
Not yet recruiting NCT06071052 - TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens N/A
Recruiting NCT04491929 - Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases
Not yet recruiting NCT06050200 - TANGO-LIVER Three Arm Nuclear Growth Observation in Liver Surgery N/A
Enrolling by invitation NCT03444194 - Treatment Response Evaluation in Patients With Non-resectable Colorectal Liver Metastases A Feasibility Study N/A
Not yet recruiting NCT05884723 - Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis N/A
Not yet recruiting NCT06185556 - COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases Phase 2/Phase 3
Recruiting NCT05755672 - On-treatment Biomarkers in Metastatic Colorectal Cancer for Life
Recruiting NCT04595266 - Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease Phase 2
Recruiting NCT04701281 - Study of Intra-Arterial Oxaliplatin Plus Capecitabine to Treat Liver Metastases From Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05775146 - SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases Phase 2
Recruiting NCT06200831 - Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases N/A
Active, not recruiting NCT04046445 - Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer Phase 1